Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won't cast light on.
about
Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.Revisiting financial conflicts of interest in FDA advisory committeesThe ICMJE Recommendations and pharmaceutical marketing--strengths, weaknesses and the unsolved problem of attribution in publication ethics.Understanding pharmaceutical research manipulation in the context of accounting manipulation.Rooting out institutional corruption to manage inappropriate off-label drug use.To see, or not to see, that is the question: can public disclosure really improve transparency between medicine and the pharmaceutical industry?The sunshine act and medical publications: Guidance from professional medical associations.Association of Gender With Financial Relationships Between Industry and Academic Otolaryngologists.Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey.Patients' participation in decision-making in the medical field--'projectification' of patients in a neoliberal framed healthcare system.Trust and transparency: patient perceptions of physicians' financial relationships with pharmaceutical companies.Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics.Marketing trials, marketing tricks - how to spot them and how to stop them.Physicians under the influence: social psychology and industry marketing strategies.Introduction: Institutional corruption and the pharmaceutical policy.Scientism in Medical Education and the Improvement of Medical Care: Opioids, Competencies, and Social Accountability.From community to commodity: the ethics of pharma-funded social networking sites for physicians.Drug firms, the codification of diagnostic categories, and bias in clinical guidelines.Corporate practices and health: a framework and mechanisms.Industry Payments to Physicians for Opioid Products, 2013-2015.Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
P2860
Q33938276-A8EFEBF7-367A-48DE-8189-8F426A40C3CBQ34460311-E602DCAF-050F-42AE-BB1F-31A31D9634A2Q36765612-F2EDFB24-7647-47A0-A3A8-C8B537B8DE88Q38148607-723EDCFE-FC53-4DF7-8B1B-E00EF4FC1D82Q38148609-8A24AE28-B11D-4984-8364-7D7614AC6A9FQ38201695-218B8C20-31A0-4F06-AC3D-86DFB882A9FEQ38574598-35203BDD-E0C7-486E-B617-AB0F845FBC8DQ38750791-EFD9C8BF-98E6-4134-B45C-AF579AE3B8B1Q38925837-CB7877A3-FE37-483B-83B8-27A6ED9ECB01Q39010665-6A109CAB-2C8B-4CED-86C5-EED10866AD3BQ39063299-2B98ACC1-CE8C-4B20-A4D2-96DA37139C2DQ41991279-A8ED502A-B6A7-406F-84E9-DDA6173B1B7FQ42317700-5113B52B-26D4-4F8E-88C1-453F1EB9BD45Q43982295-84EC4DAF-8B69-4319-9C30-B3EB84AE8D5DQ44433738-29C262AD-65C2-4601-84DD-24E6E4A4FA43Q47664123-C883C496-DC11-49BC-9FC6-98377DDACDF4Q48158783-BB2456A4-CF8D-45EB-8A11-096E5372A5FFQ48158796-52C5BCF7-2DE7-4403-88B0-DC8D6953591CQ49962849-A61C5AA8-1ECD-473A-BE6C-B5B5BDF146B8Q52313786-A943763E-81DA-4AAD-A42C-B0DCE36A07FAQ55342152-0C41FEA6-5AE2-4904-B5CA-889CD150CBD9
P2860
Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won't cast light on.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Key opinion leaders and the co ...... will and won't cast light on.
@en
Key opinion leaders and the co ...... will and won't cast light on.
@nl
type
label
Key opinion leaders and the co ...... will and won't cast light on.
@en
Key opinion leaders and the co ...... will and won't cast light on.
@nl
prefLabel
Key opinion leaders and the co ...... will and won't cast light on.
@en
Key opinion leaders and the co ...... will and won't cast light on.
@nl
P2860
P356
P1476
Key opinion leaders and the co ...... will and won't cast light on.
@en
P2093
Sergio Sismondo
P2860
P304
P356
10.1111/JLME.12073
P577
2013-01-01T00:00:00Z